Singapore, Oct. 31 -- Nanjing IASO Biotechnology has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean market for the treatment of multiple myeloma.

This partnership aims to provide a new therapeutic option for Korean patients with multiple myeloma, and GC Cell plans to sequentially pursue domestic regulatory approval and commercialisation of Fucaso.

Multiple myeloma is an incurable form of blood cancer with a high risk of relapse, most commonly affecting older adults. In South Korea, the number of multiple myeloma patients has been increasing annually due to an aging population.

Many patients eventually develop resistance or refractoriness to existing treatm...